Loading cancer entity…
Loading cancer entity…
Clinical trials
144 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05885399 | The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | unknown | Phase 2 | 5 | Peking Union Medical College HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885386 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05883085 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT00874614 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | unknown | Phase 2 | 74 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2023source: clinicaltrials